GRTS 40% workforce reduction: https://finance.yahoo.com/news/gritstone-bio-announces-workforce-reduction-210500296.html The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study. That's the BARDA funding they're referring to. GRTS previously delayed the start of the phase-2b COVID-vaccine trial due to CMC issues.